Diagnostic value of p16 methylation for malignant pleural effusion a meta-analysis

Abstract

Objective: To evaluate the overall diagnostic performance of the p16 methylation for diagnosing malignant pleural effusion (MPE). Methods: All published literature in English and Chinese were reviewed. Sensitivity, specificity, likelihood ratio and diagnostic odds ratio (DOR) were pooled by using random-effects model or fixedeffects model. Summary receiver operating characteristic (SROC) curve was used to evaluate the overall diagnostic value. Results: Six studies were included with a total of 378 cases. The sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and DOR of p16 methylation in the diagnosis of MPE were 0.41 [95% confidence interval (CI) 0.35, 0.48], 0.97 [95% CI 0.93, 0.99], 9.57 [95% CI 4.53, 20.20], 0.61 [95% CI 0.45, 0.82] and 19.82 [95% CI 8.35, 47.04], respectively. The area under the curve (AUC) was 0.864. Conclusion: Pleural p16 methylation test plays a useful role in the diagnosis of MPE.